| Missing (N=50) |
PD-L1 TPS (N=42) |
P-value | |
|---|---|---|---|
| Age(years) | |||
| Mean (SD) | 62.9 (8.28) | 63.8 (7.51) | 0.507 |
| Median [Min, Max] | 65.0 [35.0, 75.0] | 64.5 [47.0, 76.0] | |
| Sex | |||
| FeMale | 6 (12.0%) | 4 (9.5%) | 0.965 |
| Male | 44 (88.0%) | 38 (90.5%) | |
| Smoking | |||
| No | 12 (24.0%) | 4 (9.5%) | 0.121 |
| Yes | 38 (76.0%) | 38 (90.5%) | |
| Pathologic subtype | |||
| Non squamous | 22 (44.0%) | 26 (61.9%) | 0.133 |
| Squamous | 28 (56.0%) | 16 (38.1%) | |
| PFS(months) | |||
| Mean (SD) | 12.7 (9.50) | 18.5 (11.0) | 0.421 |
| Median [Min, Max] | 9.80 [1.47, 36.9] | 18.7 [0.600, 37.4] | |
| OS(months) | |||
| Mean (SD) | 18.9 (11.3) | 22.9 (9.59) | 0.392 |
| Median [Min, Max] | 18.7 [1.47, 38.3] | 24.2 [1.33, 39.3] | |
| Clinical benefit | |||
| DCB | 36 (72.0%) | 33 (78.6%) | 0.629 |
| NDB | 14 (28.0%) | 9 (21.4%) | |
| LDH | |||
| Mean (SD) | 273 (195) | 203 (93.3) | 0.319 |
| Median [Min, Max] | 207 [119, 1110] | 180 [66.7, 560] | |
| Missing | 1 (2.0%) | 0 (0%) | |
| NLR | |||
| Mean (SD) | 4.33 (2.16) | 3.26 (1.77) | 0.362 |
| Median [Min, Max] | 3.72 [1.04, 9.80] | 2.90 [1.25, 8.79] | |
| Bone metastasis | |||
| No | 31 (62.0%) | 28 (66.7%) | 0.805 |
| Yes | 19 (38.0%) | 14 (33.3%) | |
| Brain metastasis | |||
| No | 43 (86.0%) | 33 (78.6%) | 0.509 |
| Yes | 7 (14.0%) | 9 (21.4%) | |
| Liver metastasis | |||
| No | 44 (88.0%) | 40 (95.2%) | 0.392 |
| Yes | 6 (12.0%) | 2 (4.8%) | |
| Pleura metastasis | |||
| No | 36 (72.0%) | 33 (78.6%) | 0.629 |
| Yes | 14 (28.0%) | 9 (21.4%) | |
| Lymph metastasis | |||
| No | 28 (56.0%) | 18 (42.9%) | 0.295 |
| Yes | 22 (44.0%) | 24 (57.1%) |